Takeover rumors are common, and thoughts that Switzerland's Hoffmann-La Roche is on the prowl to ensure its big league status (especially once fellow Swiss firms Sandoz and Ciba merge into Novartis) are prominent.
Till now, Roche's eyes have been rumored to be set on the UK's Zeneca, but now the word is "it is after SmithKline Beecham" (or perhaps Sweden's Astra). Typically on rumors, the companies involved have "no comment." However, it is worth noting that to buy SB, Roche would have to lay out something in the $50 billion region, and that's a lot, even for Roche.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze